{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:32Z","timestamp":1793971952895,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018508","name":"Japan Medical Association Center for Clinical Trials","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.lungcan.2024.107557","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T16:14:57Z","timestamp":1711815297000},"page":"107557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-5923","authenticated-orcid":false,"given":"Seiji","family":"Niho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0613-9487","authenticated-orcid":false,"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Mizugaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-546X","authenticated-orcid":false,"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9175-3627","authenticated-orcid":false,"given":"Yasuhito","family":"Fujisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-073X","authenticated-orcid":false,"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-2274","authenticated-orcid":false,"given":"Toshiyuki","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3610-3331","authenticated-orcid":false,"given":"Hiroki","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107557_b0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1067\/mtc.2003.133","article-title":"Aggressive multimodality treatment of invasive thymic carcinoma","volume":"125","author":"Greene","year":"2003","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.107557_b0010","doi-asserted-by":"crossref","unstructured":"A. Marx, J.K.C. Chan, L. Chalabreysse, S. Dacic, F. Detterbeck, C.A. French, J.L. Hornick, H. Inagaki, D. Jain, A.J. Lazar, M. Marino, E.M. Marom, A.L. Moreira, A.G. Nicholson, M. Noguchi, D. Nonaka, M.G. Papotti, D. Porubsky, L.M. Sholl, H. Tateyama, V. Thomas de Montpr\u00e9ville, W.D. Travis, A. Rajan, A.C. Roden, P. Str\u00f6bel, The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors?, J. Thorac. Oncol. 17 (2022) 200\u2013213. Doi: 10.1016\/j.jtho.2021.10.010.","DOI":"10.1016\/j.jtho.2021.10.010"},{"key":"10.1016\/j.lungcan.2024.107557_b0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","article-title":"Thymic carcinomas-a concise multidisciplinary update on recent developments from the thymic carcinoma working group of the international thymic malignancy interest group","volume":"17","author":"Roden","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0020","doi-asserted-by":"crossref","first-page":"e0227197","DOI":"10.1371\/journal.pone.0227197","article-title":"Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States","volume":"14","author":"Hsu","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.lungcan.2024.107557_b0025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/annonc\/mdu033","article-title":"Rare cancers: work in progress in Europe","volume":"25","author":"Casali","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0030","doi-asserted-by":"crossref","first-page":"S589","DOI":"10.21037\/jtd.2016.06.44","article-title":"Trends and current status of general thoracic surgery in Japan revealed by review of nationwide databases","volume":"8","author":"Okumura","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2024.107557_b0035","unstructured":"National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology: Thymomas and thymic carcinoma. 2023; version 1. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1469 (accessed 19 April 2023)."},{"key":"10.1016\/j.lungcan.2024.107557_b0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"ESMO guidelines committee, lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0045","unstructured":"The Japan Lung Cancer Society, Guidelines for diagnosis and treatment lung cancer \/malignant pleural mesothelioma\/thymic tumor 2022 Edition. https:\/\/www.haigan.gr.jp\/guideline\/2022\/. [in Japanese] (accessed 19 April 2023)."},{"key":"10.1016\/j.lungcan.2024.107557_b0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13019-016-0468-1","article-title":"Tumor-related gene expression levels in thymic carcinoma and type B3 thymoma","volume":"11","author":"Karube","year":"2016","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2024.107557_b0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00595-003-2722-0","article-title":"Elevated serum epidermal growth factor receptor level in stage IV thymoma","volume":"34","author":"Sasaki","year":"2004","journal-title":"Surg. Today."},{"key":"10.1016\/j.lungcan.2024.107557_b0060","doi-asserted-by":"crossref","unstructured":"R. Lattanzio, R. La Sorda, F. Facciolo, S. Sioletic, L. Lauriola, R. Martucci, E. Gallo, G. Palmieri, A. Evoli, G. Alessandrini, L. Ruco, E.A. Rendina, M. Truini, R. Chiarle, A. Barreca, A. Pich, S. Ascani, D. Remotti, G. Tunesi, P. Granone, G.B. Ratto, F. Puma, E. Pescarmona, M. Piantelli, M. Marino; Thymic Epithelial Tumor Working Group; S. Carlini, V. Cerasoli, F. Corzani, E. Melis, M. Filippetti, P. Canalini, G. Palestro, M. Lalle, E. Ruffini, A. Ceribelli, M. Rinaldi, Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study, Lung Cancer. 85 (2014) 191\u2013196. Doi: 10.1016\/j.lungcan.2014.05.010.","DOI":"10.1016\/j.lungcan.2014.05.010"},{"key":"10.1016\/j.lungcan.2024.107557_b0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/ph14040316","article-title":"An overview on molecular characterization of thymic tumors: old and new targets for clinical advances","volume":"14","author":"Tateo","year":"2021","journal-title":"Pharmaceuticals (basel)."},{"key":"10.1016\/j.lungcan.2024.107557_b0070","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107557_b0075","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.lungcan.2024.107557_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J. Thyroid Res."},{"key":"10.1016\/j.lungcan.2024.107557_b0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc. Cell."},{"key":"10.1016\/j.lungcan.2024.107557_b0090","doi-asserted-by":"crossref","first-page":"e0231828","DOI":"10.1371\/journal.pone.0231828","article-title":"Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Kirino","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.lungcan.2024.107557_b0095","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.21873\/anticanres.13710","article-title":"Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma","volume":"39","author":"Takahashi","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2024.107557_b0100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1507\/endocrj.EJ20-0754","article-title":"Prognostic significance of 8 weeks\u2019 relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients","volume":"68","author":"Fukuda","year":"2021","journal-title":"Endocr, J."},{"key":"10.1016\/j.lungcan.2024.107557_b0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0110","unstructured":"H. Murakami, J. Sato, M. Satouchi, S. Itoh, Y. Okuma, S. Niho, H. Mizugaki, Y. Fujisaka, T. Kozuki, Y. Ohe, T. Tamai, H. Ikezawa, N. Yamamoto, Association between dose reduction\/dose intensity and efficacy of lenvatinib for thymic carcinoma. The 62nd Annual Meeting of the Japan Lung Cancer Society, Abstract WS6-6."},{"key":"10.1016\/j.lungcan.2024.107557_b0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0135","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107557_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jtcvs.2014.09.124","article-title":"Thymic carcinoma outcomes and prognosis: results of an international analysis","volume":"149","author":"Ahmad","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2024.107557_b0145","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers11111769","article-title":"Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma: Experience in clinical settings","volume":"11","author":"Sasaki","year":"2019","journal-title":"Cancers (basel)."},{"key":"10.1016\/j.lungcan.2024.107557_b0150","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.21873\/anticanres.13802","article-title":"Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo","volume":"39","author":"Ogasawara","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2024.107557_b0155","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s005950170021","article-title":"Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms","volume":"31","author":"Sasaki","year":"2001","journal-title":"Surg. Today."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T22:33:13Z","timestamp":1715639593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"alternative-id":["S0169500224000904"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107557","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107557"}}